- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04462757
SCIL-1Ra in COVID-19 Feasibility & PK/PD (SCIL_COV19)
Subcutaneous and Intravenous IL-1Ra (Anakinra) in COVID-19 Infection - Feasibility & Pharmacokinetics/Pharmacodynamics Study
The current COVID-19 pandemic is a worldwide healthcare crisis. Of concern is the large number of patients that are/will require mechanical ventilation, and the associated strain that this will place on healthcare resources. At present, there are no specific therapeutic interventions directed at COVID-19 infection. However, observational data suggest that there is a subgroup of patients that demonstrate a hyperinflammatory response in response to COVID-19 and have a higher requirement for Critical Care and higher mortality.
There is a strong case for the use of the naturally occurring anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) in these patients. Anakinra is a recombinant form of IL-1Ra that is licensed for clinical use. Success of use of anakinra in COVID-19 trials will be greatly enhanced by robust scientific evidence and established pharmacokinetics which inform the most effective dosing regimens. The latter is especially important when, as in the case of anakinra, drug supplies are limited, the drug has short half-life and clinical ease of application is critical.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom, M13 9WL
- Manchester Univesity NHS Foundation Trust
-
Salford, United Kingdom, M6 8HD
- Salford Royal NHS Foundation Tust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient age 18 or above.
- Clinically suspected/proven COVID-19.
- Requiring organ support with one or more of:
- Non-invasive or invasive ventilatory support
- Receiving infusion of vasopressor or inotropes or both.
- No concomitant health problems that, in the opinion of the PI or designee in agreement with the treating clinician, would interfere with participation, administration of study drug or assessment of outcomes including safety.
Exclusion Criteria:
- More than 24h has elapsed since CCU admission.
- Death is deemed to be imminent and inevitable during the next 24h.
- One or more of: the patient, substitute decision-maker or the attending physician are not committed to full active treatment.
- Known condition resulting in ongoing immunosuppression including neutropenia (count < 1.5 x 10^9/L) prior to hospitalisation, malignancy, latent tuberculosis or chronic liver disease (if known).
- Previous or current treatment with anakinra or medication suspected of interacting with anakinra, listed in the drug SmPC, known at the time of trial entry or previous participation in this trial.
- Known to have received active treatment in a clinical trial of an investigational immunomodulatory agent (not including corticosteroids) within 30 days prior to study entry.
- Known to be pregnant or breast feeding or inability to reliably confirm that the patient is not pregnant.
- Known allergy to anakinra or any of the excipients listed in the drug SmPC
- Known allergy to other products that are produced by DNA technology using the micro-organism E. coli (e.g. Escherichia coli derived protein).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Subcutaneous Arm
100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.
|
100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
Other Names:
|
ACTIVE_COMPARATOR: Intravenous Arm
100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours.
|
100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma IL-1Ra levels
Time Frame: 1 week
|
Plasma IL-1Ra levels from Day 1 to Day 7 following administration of SC anakinra in patients with SARS-CoV-2
|
1 week
|
Plasma IL-6 levels
Time Frame: 1 week
|
Plasma IL-6 levels from Day 1 to Day 7 following administration of SC anakinra in patients with SARS-CoV-2
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma markers
Time Frame: 2 weeks
|
Plasma markers including IL-6 from Day 1 to Day 14 in all participants
|
2 weeks
|
Plasma markers
Time Frame: 2 weeks
|
Plasma markers including CRP from Day 1 to Day 14 in all participants
|
2 weeks
|
Plasma markers
Time Frame: 2 weeks
|
Plasma markers including CXCL9 from Day 1 to Day 14 in all participants
|
2 weeks
|
Plasma markers
Time Frame: 2 weeks
|
Plasma markers including IL-1 from Day 1 to Day 14 in all participants
|
2 weeks
|
Plasma markers
Time Frame: 2 weeks
|
Plasma markers including IL-2 from Day 1 to Day 14 in all participants
|
2 weeks
|
Plasma markers
Time Frame: 2 weeks
|
Plasma markers including HMBG-1 from Day 1 to Day 14 in all participants
|
2 weeks
|
Plasma markers
Time Frame: 2 weeks
|
Plasma markers including IL-33 from Day 1 to Day 14 in all participants
|
2 weeks
|
Safety Endpoints related to the Serious adverse reactions of the IMP
Time Frame: 2 weeks
|
Safety endpoints include: a. Severe fatal or life-threatening serious adverse reactions (duration of IMP plus 30h from last dose). |
2 weeks
|
Safety Endpoints related to the anaphylactic reactions of the IMP
Time Frame: 2 weeks
|
Safety endpoints include: b. Anaphylactic/anaphylactoid reactions (duration of IMP plus 30h from last dose). |
2 weeks
|
Safety Endpoints related to neutropenia caused by the IMP
Time Frame: 2 weeks
|
Safety endpoints include: c. Severe neutropenia (< 1.5 x 109 /L) (duration of IMP) |
2 weeks
|
Safety Endpoints related to any severe laboratory abnormalities
Time Frame: 2 weeks
|
Safety endpoints include: d. IMP related severe laboratory abnormalities (duration of IMP) |
2 weeks
|
Feasibility endpoints related to IMP and deviations
Time Frame: 2 weeks
|
Feasibility endpoints include protocol deviations in terms of timing and delivery of scheduled medication.
|
2 weeks
|
Exploratory Data on Clinical efficacy by time to recovery
Time Frame: 4 weeks
|
Exploratory data on clinical efficacy as defined by: a. Time to recovery defined by hospital discharge or improvement of two points on the ordinal scale: not hospitalised; hospitalised without need for supplemental oxygen; requiring supplemental oxygen; requiring HFNC or non-invasive mechanical ventilation; requiring ECMO or mechanical intervention; dead. Improvement mechanical ventilation (from recruitment to time of ventilation) |
4 weeks
|
Exploratory Data on Clinical efficacy
Time Frame: 4 weeks
|
Exploratory data on clinical efficacy as defined by: b. Ventilation free days (at 28 days) |
4 weeks
|
Exploratory Data on Clinical efficacy of the ordinal scale
Time Frame: 4 weeks
|
Exploratory data on clinical efficacy as defined by: c. Status on the above ordinal scale (at 14 and 28 days) |
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Timothy Felton, Dr, University of Manchester
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 282110
- 2020-001636-95 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Anakinra 100Mg/0.67Ml Inj Syringe
-
Northwell HealthSwedish Orphan BiovitrumRecruitingMeniere's Disease | Autoimmune Inner Ear DiseaseUnited States
-
Azienda Sanitaria-Universitaria Integrata di UdineUniversity of UdineRecruitingAcute Respiratory Distress SyndromeItaly
-
University of California, San DiegoRecruitingEndometriosis | Anakinra | Markers of InflammationUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingChronic Kidney Disease | Gout | Renal TransplantationFrance
-
Il-Yang Pharm. Co., Ltd.Completed
-
Green Cross CorporationCompletedInfluenzaKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.Completed
-
Boryung Pharmaceutical Co., LtdCompletedPertussis | Tetanus | Diphtheria | PoliomyelitisThailand, Korea, Republic of
-
Il-Yang Pharm. Co., Ltd.Not yet recruiting
-
Green Cross CorporationUnknownInfluenza VaccineKorea, Republic of